Psychedelics and neonihilism: connectedness in a meaningless world.
connectedness
meaning
neonihilism
psychedelics
psychotherapy
Journal
Frontiers in psychology
ISSN: 1664-1078
Titre abrégé: Front Psychol
Pays: Switzerland
ID NLM: 101550902
Informations de publication
Date de publication:
2023
2023
Historique:
received:
16
12
2022
accepted:
24
04
2023
medline:
25
8
2023
pubmed:
25
8
2023
entrez:
25
8
2023
Statut:
epublish
Résumé
The resurgence of psychedelic research explicitly targets treating mental health conditions largely through psychedelics-assisted psychotherapy. Current theories about mechanisms of change in psychedelics-assisted psychotherapy focus on mystical experiences as the main driver of symptom improvement. During these mystical experiences, participants report an enhanced sense of salience, connectedness, and meaning. Simultaneously, a growing psychedelic culture is also cultivating the use of psychedelics as medicine for relieving symptoms of anxiety and depression and promoting cognitive functions. We argue that an integral part of the excitement around the resurgence in psychedelics is in response to a meaning and alienation crisis that correlates with rising rates of anxiety and depression. Framing the absence of meaning as neonihilism, a contemporary correlate to the 19
Identifiants
pubmed: 37621941
doi: 10.3389/fpsyg.2023.1125780
pmc: PMC10445489
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1125780Informations de copyright
Copyright © 2023 Plesa and Petranker.
Déclaration de conflit d'intérêts
RP is a consultant for Naya Technologies Inc. The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Int J Neuropsychopharmacol. 2023 Mar 22;26(3):155-188
pubmed: 36272145
ACS Pharmacol Transl Sci. 2020 Dec 10;4(2):568-572
pubmed: 33861219
Prog Brain Res. 2018;242:69-96
pubmed: 30471683
J Anxiety Disord. 2020 Dec;76:102313
pubmed: 32992267
Psychopharmacology (Berl). 2018 Feb;235(2):547-550
pubmed: 28795211
Epidemiol Psychiatr Sci. 2022 Dec 02;31:e86
pubmed: 36459133
Front Psychol. 2021 Nov 23;12:730031
pubmed: 34887799
J Pers Soc Psychol. 1994 Dec;67(6):1049-62
pubmed: 7815301
Psychopharmacology (Berl). 2022 Nov;239(11):3461-3483
pubmed: 35939083
EClinicalMedicine. 2020 Oct 02;27:100557
pubmed: 33073220
J Psychoactive Drugs. 1997 Apr-Jun;29(2):213-6
pubmed: 9250949
Pharmacol Rev. 2016 Apr;68(2):264-355
pubmed: 26841800
Nat Commun. 2022 Oct 3;13(1):5812
pubmed: 36192411
Evid Based Complement Alternat Med. 2020 Aug 14;2020:4048916
pubmed: 32855650
Acad Psychiatry. 2021 Oct;45(5):539-544
pubmed: 33660237
Front Neurosci. 2018 Mar 06;12:129
pubmed: 29559884
Psychopharmacology (Berl). 2022 Dec;239(12):3771-3777
pubmed: 36289109
Proc Natl Acad Sci U S A. 2016 Apr 26;113(17):4853-8
pubmed: 27071089
Front Psychol. 2021 Nov 25;12:749788
pubmed: 34899488
J Antibiot (Tokyo). 2020 Oct;73(10):679-686
pubmed: 32398764
Clin Psychol Rev. 2011 Jun;31(4):617-25
pubmed: 21482320
Curr Biol. 2017 Feb 6;27(3):451-457
pubmed: 28132813
Pharmacol Rev. 2019 Jul;71(3):316-344
pubmed: 31221820
EClinicalMedicine. 2020 Sep 24;27:100538
pubmed: 33150319
Front Psychol. 2020 Jul 10;11:1681
pubmed: 32754101
Drugs (Abingdon Engl). 2021;28(3):215-226
pubmed: 34349358
Front Psychol. 2018 Aug 15;9:1424
pubmed: 30174629
Risk Manag Healthc Policy. 2021 Mar 05;14:901-910
pubmed: 33707976
Health (London). 2009 Jul;13(4):389-406
pubmed: 19491233
J Psychoactive Drugs. 2017 Jul-Aug;49(3):182-191
pubmed: 28443703
Curr Psychiatry Rep. 2017 Sep 19;19(11):81
pubmed: 28924828
J Psychopharmacol. 2020 Jun;34(6):623-635
pubmed: 32255395
Front Psychiatry. 2022 Jul 12;13:917199
pubmed: 35923458
J Eval Clin Pract. 2016 Aug;22(4):580-7
pubmed: 27149914
BMJ. 2012 May 28;344:e3502
pubmed: 22645185
J Pers. 2008 Apr;76(2):199-228
pubmed: 18331281
Front Psychol. 2022 Aug 04;13:824077
pubmed: 35992410
Eur Neuropsychopharmacol. 2021 Sep;50:121-132
pubmed: 34246868
Philos Ethics Humanit Med. 2012 Jan 13;7:2
pubmed: 22243976
Neuropharmacology. 2023 Feb 1;223:109300
pubmed: 36334767
Am Psychol. 2000 Jan;55(1):68-78
pubmed: 11392867
JMIR Ment Health. 2020 Jun 2;7(6):e18472
pubmed: 32484445
J Psychoactive Drugs. 2019 Apr-Jun;51(2):174-188
pubmed: 30950777
Soc Sci Med. 2015 Mar;128:316-26
pubmed: 25577953
J Psychopharmacol. 2022 Mar;36(3):258-272
pubmed: 35107059
Psychother Psychosom. 2019;88(4):193-202
pubmed: 31340212
Int J Drug Policy. 2022 Jul;105:103704
pubmed: 35544971
Proc Natl Acad Sci U S A. 2020 Feb 4;117(5):2338-2346
pubmed: 31964815
Curr Opin Psychiatry. 2019 Jan;32(1):16-21
pubmed: 30394903
PLoS One. 2010 Aug 31;5(8):e12412
pubmed: 20824211